Description: LadRx Corporation, a biopharmaceutical company, engages in the discovery and development of therapeutics to treat patients with cancer. The company's advanced drug conjugate, aldoxorubicin that is in late-stage clinical trials is a version of anti-cancer drug doxorubicin. Its pre-clinical therapeutics comprise linker activated drug releases 7, 8, 9, and 10 targeted against cancer The company was formerly known as CytRx Corporation and changed its name to LadRx Corporation in September 2022. LadRx Corporation was incorporated in 1985 and is headquartered in Los Angeles, California.
Home Page: www.ladrxcorp.com
11726 San Vicente Boulevard
Los Angeles,
CA
90049
United States
Phone:
310 826 5648
Officers
| Name | Title |
|---|---|
| Dr. Stephen Snowdy Ph.D. | Chief Executive Officer |
| Mr. John Y. Caloz CPA | CFO, Treasurer, Senior VP & Corporate Secretary |
| Molly Carey Poarch | Global & U.S. Head of Corporate Communications |
Exchange: OTCQB
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.9401 |
| Price-to-Sales TTM: | 34.4758 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 2 |